Education
Master’s of Science in Clinical Psychopharmacology
Pre-doctoral and Post-doctoral Training
Harvard Medical School/Massachusetts General Hospital
Licensure
Florida Board of Psychology, License #PY0004519
Board Certification
American Board of Professional Psychology
Diplomate in Clinical Psychology, Certificate #5039
Board Appointments CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
Academic Appointments
Clinical Fellow in the Department of Psychiatry
Instructor in the Department of Psychiatry
Voluntary Assistant Professor in the Department of Neurology
Adjunct Associate Professor in the Department of Psychology
Staff Appointments
Massachusetts General Hospital, Boston, MA
New England Memorial Hospital, Stoneham, MA
Professional Experience
Coordinator of Inpatient Training for Pre-doctoral Internship
Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA
Director, Mobile Crisis Services for Hurricane Andrew Relief Effort
Director, Assessment and Emergency Service
AuroraCare Behavioral Managed Care Company, Miami, FL
Baptist Memory Disorders Center, Miami, FL
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
Committee Assignments
South Florida Interprofessional Council Representative
Psychopharmacology Committee, Chairperson
PsychStar Behavioral Managed Care Company
Alzheimer’s Association of Greater Miami
Quality Improvement Committee, Chairperson
Memberships in Professional Associations
International Neuropsychological Society
Original Reports
Rivas-Vazquez, R., & Blais, M. (1997). Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists. Professional Psychology: Research and Practice, 28, 526–536.
Carrazana, E., DeToledo, J., Tatum, W., Wheeler, S., & Rivas-Vazquez, R. (1999). Epilepsy and religious experiences: Voodoo possession. Epilepsia, 40, 239–241.
Rivas-Vazquez, R., Johnson S.L., Blais, M., & Rey, G. (1999). Selective serotonin reuptake inhibitor discontinuation syndrome: Understanding, recognition and management for psychologists. Professional Psychology: Research and Practice, 30, 464–469.
Rey, G.J., Feldman, E., Rivas-Vazquez, R., Levin, B.E., & Benton, A.L. (1999). Neuropsychological test development and normative data on Hispanics. Archives of Clinical Neuropsychology, 14, 593–601.
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
Rivas-Vazquez, R., Blais, M.A., Rey, G.J., & Rivas-Vazquez, A. (2000). Atypical antipsychotics: Pharmacologic profiles and psychologic implications. Professional Psychology: Research and Practice, 31, 628–640.
Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., Blais, M.A., & Racher, D.A. (2000). Alzheimer’s disease: Pharmacologic treatment and management. The Clinical Neuropsychologist, 14, 93–109.
Rivas-Vazquez, R., Rivas-Vazquez A, Rey, G.J., & Blais, M.A. (2000). Sexual dysfunction associated with antidepressant treatment. Professional Psychology: Research and Practice, 31, 641–651.
Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Wheeler, S.D. (2000). Selective serotonin reuptake inhibitor discontinuation syndrome: Three cases presenting to a neurologic practice. The Neurologist, 6, 348–352.
9) Rivas-Vazquez, R. (2001). Antidepressants as first-line agents in the current
pharmacotherapy of anxiety disorders. Professional Psychology: Research and Practice, 32, 101–104.
10) Carrazana, E., Rey, G., Rivas-Vazquez, R., & Tatum, W. (2001). Ictal “alien” hand
syndrome. Epilepsy and Behavior, 2, 61–64.
11) Rivas-Vazquez, R., Blais, M., Rey, G., & Rivas-Vazquez, A. (2001). A brief reminder
about documenting the psychological consultation. Professional Psychology: Research and Practice, 32, 194–199.
12) Rivas-Vazquez, R. (2001). Reboxetine: Refocusing on the role of norepinephrine in
the treatment of depression. Professional Psychology: Research and Practice, 32, 211–214.
13) Rey, G.J., Feldman, E., Hernandez, D., Levin, B.E., Rivas-Vazquez, R., LeBlanc,
W.G., & Benton, A.L. (2001). Application of the Multilingual Aphasia Examination - Spanish in the evaluation of Hispanic patients post-traumatic brain injury. The Clinical Neuropsychologist, 15, 13–18.
14) Rivas-Vazquez, R. (2001). St. John’s wort (Hypericum perforatum): Practical
considerations based on the evidence. Professional Psychology: Research and Practice, 32, 329–332.
15) Carrazana, E.J., Rivas-Vazquez, R., Rey J, & Rey, G.J. (2001). SSRI discontinuation
syndrome exacerbated by buspirone (letter). American Journal of Psychiatry, 158, 966–967.
16) Rivas-Vazquez, R. (2001). Cholinesterase inhibitors: Current pharmacological
treatments for Alzheimer's disease. Professional Psychology: Research and Practice, 32, 433–436.
17) Blais, M., Rivas-Vazquez, R., Rey, G.J., Racher, D.A., & Carrazana, E.J. (2001).
Treatment and management of Alzheimer's disease. Clinical Geriatrics, 9, 58–65.
18) Rivas-Vazquez, R. (2001). Understanding drug interactions. Professional Psychology: Research and Practice, 32, 543–547.
19) Rivas-Vazquez, R., Rivas-Vazquez, A., Blais, M., Rey, G.J., Rivas-Vasquez, F.,
Jacobo, M., & Carrazana, E.J. (2001). Development of a Spanish version of the Schwartz Outcome Scale - 10: A brief mental health outcome measure. Journal of Personality Assessment, 77, 436–446.
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
20) Rivas-Vazquez, R. (2001). Ziprasidone: Pharmacological and clinical profile of the
newest atypical antipsychotic. Professional Psychology: Research and Practice, 32, 662–665.
21) Rivas-Vazquez, R., & Blais, M. (2002). Pharmacologic treatment of personality
disorders. Professional Psychology: Research and Practice, 33, 101–104.
22) Rivas-Vazquez, R., Johnson, S.L., Rey, G.J., & Blais, M. (2002). Current treatments
for bipolar disorder: A review and update for psychologists. Professional Psychology: Research and Practice, 33, 212–223.
23) Rivas-Vazquez, R., & Rey, J. (2002). Weight gain and metabolic disturbances
associated with the atypical antipsychotics. Professional Psychology: Research and Practice, 33, 341–344.
24) Rivas-Vazquez, R., & Delgado, L. (2002). Clinical and toxic effects of MDMA
(“Ecstasy”). Professional Psychology: Research and Practice, 33, 422–425.
25) Rivas-Vazquez, R., & Mendez, C.I. (2002). Overview of the drug approval process.
Professional Psychology: Research and Practice, 33, 502–506.
26) Blais, M.A., Matthews, J., Lipkis-Orlando, R., O’Keefe, S.M., Jacobo, M., Rivas-
Vazquez, R.A, & Summergrad, P. (2002). Development and application of a multi-faceted tool for evaluating inpatient psychiatric care. Administration and Policy in Mental Health, 30, 159–172.
27) Rivas-Vazquez, R.A. (2003). Aripiprazole: A novel antipsychotic with dopamine
stabilizing properties. Professional Psychology: Research and Practice, 34, 108–111.
28) Rivas-Vazquez, R.A., & Perel, J.M. (2003). The role of stereochemistry and chiral
pharmacology in psychotropic drug development. Professional Psychology: Research and Practice, 34, 210–213.
29) Rivas-Vazquez, R.A. (2003). Benzodiazepines in contemporary clinical practice.
Professional Psychology: Research and Practice, 34, 324–328.
30) Feldman, L.B., & Rivas-Vazquez, R.A. (2003). Assessment and treatment of social
anxiety disorder. Professional Psychology: Research and Practice, 34, 396–405.
31) Rivas-Vazquez, R.A, & Resnick, M. (2003). The emerging role of glutamate in the
pathophysiology and treatment of psychiatric disorders. Professional Psychology: Research and Practice, 34, 444–448.
32) Rivas-Vazquez, R.A, Rice, J., & Kalman, D. (2003). Pharmacotherapy of obesity and
eating disorders. Professional Psychology: Research and Practice, 34, 562–566.
33) Rivas-Vazquez, R.A. (2003). Atomoxetine: A selective norepinephrine reuptake
inhibitor for the treatment of Attention-Deficit/Hyperactivity Disorder. Professional Psychology: Research and Practice, 34, 666–669.
34) Rivas-Vazquez, R.A, Mendez, C., Rey, G.J., & Carrazana, E.J. (2004). Mild cognitive
impairment: New neuropsychological and pharmacological target. Archives of Clinical Neuropsychology, 19, 11–27.
35) Rivas-Vazquez, R.A, Saffa-Biller, D., Ruiz, I., Blais, M.A., & Rivas-Vazquez, A.
(2004). Current issues in anxiety and depression: Comorbid, mixed and subthreshold disorders. Professional Psychology: Research and Practice, 35, 74–83.
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
36) Rivas-Vazquez, R.A., Sarria, M., Rey, G., Rivas-Vazquez, A., Rodriguez, J. & Jardon,
M. (2009). A relationship-based care model for jail diversion. Psychiatric Services, 60, 766–771.
37) Rivas-Vazquez, R.A., Bello, I., Sarria, M., Fernandez, N., & Rey, G.J. (2011).
Prevalence of Metabolic Syndrome in a Predominantly Cuban, Psychiatrically Ill and Homeless Population. Primary Care Companion for CNS Disorders, 13(3), e1–e5.
38) Rey, G.J., Rivas-Vazquez, R., Garaycoa, G., Mendez, C., Bello, I., & Carrazana, E.J.
(in press). A prospective study monitoring AD patients during a switch from donepezil to rivastigmine. The Neurologist.
39) Blais, M.A., Blagys, M.D., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R.,
Orlandini, E., & Bello, I. (in press). Development and initial validation of an ultra-brief measure of psychiatric symptom distress. Journal of Personality Assessment.
40) Rey, G.J., Schatz, N., Bauerlain, E.J., Bowen, B., Rivas-Vazquez, R., & Carrazana, E.J.
(under review). Transient Balint's syndrome following heart transplantation. Neuro-ophthalmology. Book Chapters
Blais, M., Smallwood, P., Groves, J., & Rivas-Vazquez R. Personality and Personality Disorders. In T. Sterns, J. Rosenbaum, M. Fava, J. Biedermen & S. Rauch (Ed.) Handbook of Comprehensive Clinical Psychiatry (2008, pp. 527-542).
Abstracts
Rivas-Vazquez, A., & Rivas-Vazquez, R. (1986, May). Family restructuring: An alternative to teen suicide. Presented at the American Association of Suicidology Conference, Atlanta, Georgia.
Rey, G.J., Feldman, E., Rivas-Vazquez, R., & Benton, A.L. (1994, August). Current trends and future of neuropsychological research with Hispanics. Presented at the annual meeting of the American Psychological Association, Los Angeles, California.
Rey, G.J., Levin, B.E., Brown, M.C., Feldman, E., Rivas-Vazquez, R., Arias, M., & Benton, A.L. (1995). Application of the Benton tests to Hispanic adults: A preliminary analysis. Journal of the International Neuropsychological Society, 1.
Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Epilepsy and religious experiences: Voodoo possession. Presented at the annual meeting of the American Epilepsy Society, San Diego, California.
Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Erroneous attribution of epileptic seizures to voodoo spirit possession. Presented at the troisieme Congres de Neurologie Tropicale, Martinique.
6) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Mendoza, R. (1999, January).
Clinical and psychosocial characteristics of Caribbean and Anglo-Saxon dementia referrals in South Florida. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana.
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
Rey, G.J., Rivas-Vazquez, R., Feldman, E., & Carrazana, E.J. (1999, January). The evaluation of “executive” functions in Hispanics. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana.
Carrazana, E.J., Wheeler, S., Aptman, M., Zwibel, H., Kobetz, S., Racher, D., Grant, T., Faradji, V., Ramirez-Mejia, C., Rivas-Vazquez, R., & Rey, G.J. (1999, December). Second generation anticonvulsants utilization in clinical neurology (abstract #10022). Presented at the annual meeting of the American Epilepsy Society, Orlando, Florida.
Rivas-Vazquez, R., Rey, G.J., Blais, M.A., Carrazana, E.J., & Schwartz, H. (2000, June). Development and validation of the Spanish version of the Schwartz Outcome Scale - 10. Presented at the 40th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida.
10) Rey, G.J., Rivas-Vazquez, R., Carrazana, E.J., Mendoza, R., Garaycoa, G., & Schwartz,
H. (2000, June). Cross-cultural comparisons of dementia referrals in South Florida: Clinical and psychosocial factors. Presented at the 40th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida.
11) Carrazana, E.J., Espinosa, I., Wheeler, S., Espinosa, J., Rey, G.J., Rivas-Vazquez, R., &
Ramirez-Mejia, C. (2000, December). Is folic acid for reduction of anticonvulsants’ teratogenic risk part of the standard neuropsychiatric clinical practice? Results of a survey. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California.
12) Rey, G.J., Carrazana, E.J., Garaycoa, G., Rivas-Vazquez, R., Espinosa, I., & Ramirez-
Mejia, C. (2000, December). Affective disorders in juvenile myoclonic epilepsy: A prospective study. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California.
13) Johnson, S.L., Rugerro, C., Winters, R., Gotlib, I.H., Ahmed, Z., & Rivas-Vazquez, R.
(2001, July). The behavioral activation system and mania: Cognitive-behavioral implications. Presented at the annual meeting of the World Congress of Behavioral and Cognitive Therapies, Vancouver, British Columbia.
14) Blagys, M.D., Blais, M.A., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R.,
Orlandini, E., & Bello, I. (2002, March). Initial development of an ultra-brief measure of psychiatric symptoms distress: The AT-25. Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas
15) Miller, D., Gonzalez, E., Rivas-Vazquez, R., & Blais, M.A. (2002, March). The Word
Association Test (WAT): A predictor of suicide? Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas
16) Rey, G.J., Garaycoa, G., Rivas-Vazquez, R., Bello, I., Campos, L., & Carrazana, E.J.
(2002, May). Clinical and neuropsychological findings in patients with Alzheimer’s disease during switch from donepezil to rivastigmine. Presented at the annual meeting of the American Geriatrics Society, Washington, D.C.
17) Rey, G.J., Rivas-Vazquez, R., Mendoza, R., Garaycoa, G., & Carrazana, E. (2005,
February). A Spanish verbal learning test: normative and clinical data. Presented at the 33rd annual International Neuropsychological Society meeting, San Louis, Missouri.
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
18) Rey, G.J., Mendez, C., Rivas-Vazquez, R., & Bello, I. (2005, February). Neuro-
psychiatric symptomatology and caregiver distress in Alzheimer’s Disease: A comparison of Hispanic and Anglosaxon groups. Presented at the 33rd annual International Neuropsychological Society meeting, San Louis, Missouri.
19) Sarria, M., Rivas-Vazquez, R.A., & Martinez, H. (2008, March). Relationship-based
care effects on jail diversion. Presented at the 2008 CMHS National GAINS Center Conference, Washington, D.C.
Other Publications
Rivas-Vazquez, R. (1990). Assessing differential levels of affective expression in bilingual subjects using the Thematic Apperception Test. Unpublished doctoral dissertation. Nova Southeastern University, Florida.
2) Rivas-Vazquez, R., & Samek, W.R. (1996). Update on prescription privileges.
Florida Psychologist, 47, 26–27.
Carrazana, E.J., & Rivas-Vazquez, R. (1999). Antiepileptic drugs in the management of mood disorders. Monograph supported by unrestricted grant from Parke-Davis/Warner Lambert.
Rivas-Vazquez, R., Johnson, S.L., Blais, M., & Rey, G. (2000). Recognizing SSRI discontinuation syndrome. Clinician’s Research Digest, 18, 3.
Lectures and Presentations
Effects of language on assessment and treatment of Hispanic patients. Presented at Massachusetts General Hospital/Chelsea Mental Health Center Teaching Rounds, May 1991, Boston, Massachusetts.
Introduction to DSM-IV. Presented at Northwest Dade Mental Health Center Grand Rounds, August 1994, Hialeah, Florida.
Clinical best practices in Medicaid managed care. Presented at Public/Private Regional Symposia: Integrating Public and Private Funding Streams and Delivery Systems in Behavioral Health Care, October 1996, Clearwater Beach, Florida.
An update on Medicaid managed care in Florida. Presented at Linking Forces VI: The Sixth Annual Children's Mental Health Conference, May 1997, Miami, Florida.
Overview of Alzheimer's disease. Presented at The Alzheimer's Association Fifth Annual Educational Forum, November 1997, Miami, Florida.
6) Alzheimer's management and treatment issues. Sponsored by the Puerto Rican
Neurophysiology Society and Pfizer-Eisai Pharmaceutical Companies. May 1998, San Juan, Puerto Rico.
Dementia ‘99: An update in diagnosis, treatment and reimbursement. Sponsored by Novartis Pharmaceuticals Corporation. February 1999, Boca Raton, Florida.
Psychological aspects of headaches. Presented at the Baptist Hospital Symposium for migraine management May 1999, Miami, Florida.
Impact of psychosocial stress on diabetes control. Presented at the Diabetes 2000: Management strategies for the new millennium. Sponsored by the Diabetes Care Centers of Baptist Health Systems. July 1999, Barcelona, Spain.
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
10) Cognitive issues associated with the use of antipsychotics in elderly patients. Presented
at the Novartis Advisory Board Meeting: Psychosis in the elderly patient. February 2002, New Orleans, Louisiana.
11) Baker act: Responsibilities and risks under the law. Presented at the South Florida
Hospital and Healthcare Association Meeting, November 2008, Weston, Florida.
Pharmaceutical Associations
Parke-Davis, Warner Lambert Pharmaceutical Speakers Bureau
Novartis Pharmaceuticals Corporation National Speakers Bureau
Research Experience
Principal Investigator, Berlex Laboratories: Multiple Sclerosis, June 1995
Bristol Myers Squibb: Generalized Anxiety Disorder, June 1997
Pharmaceuticals: Alzheimer's Disease, September 1997
Sub-investigator, Takeda: Alzheimer's Disease, March 1998
Bristol-Myers Squibb: Generalized Anxiety Disorder, April 1998
& Co., Inc.: Major Depressive Disorder, April 1998
Principal Investigator, SmithKline Beecham: Generalized Anxiety Disorder, December 1998
10) Principal Investigator, SmithKline Beecham: Posttraumatic Stress Disorder, February
11) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, February
12) Sub-investigator, Medeva Development: Pediatric Attention Deficit Hyperactivity
13) Sub-investigator, Bristol-Myers Squibb: Pediatric Generalized Anxiety Disorder, July
Bristol-Myers Squibb: Major Depressive Disorder, July 1999
Neo-Therapeutics: Alzheimer's Disease, September 1999
16) Sub-investigator, SmithKline Beecham: Premenstrual Dysphoric Disorder, September
17) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, October
18) Sub-investigator, Novartis: Mild Cognitive Impairment, December 1999 19) Sub-investigator, Tap Holdings, Inc.: Major Depressive Disorder, January 2000 20) Principal
21) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, March
23) Sub-investigator, Eli Lilly: Generalized Anxiety Disorder, August 2000
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
24) Sub-investigator, Wyeth-Ayerst: Pediatric Generalized Anxiety Disorder, August 2000 25) Sub-investigator, Wyeth-Ayerst: Adolescent Social Anxiety Disorder, August 2000 26) Sub-investigator,
Major Depressive Disorder, October 2000
27) Sub-investigator, Pfizer: Alzheimer's Disease, February 2001 28) Sub-investigator,
Forest Laboratories: Generalized Anxiety Disorder, March 2001
29) Sub-investigator, Janssen: Alzheimer's Disease, March 2001 30) Sub-investigator,
Laboratories: Moderate to Severe Alzheimer's Disease, April
31) Sub-investigator, SmithKline Beecham: Major Depressive Disorder with Anxiety,
32) Sub-investigator, Janssen: Mild Cognitive Impairment, April 2001 33) Sub-investigator,
Wyeth-Ayerst: Panic Disorder, April 2001
Forest Laboratories: Generalized Anxiety Disorder, May 2001
35) Sub-investigator, Eli Lilly: Schizophrenia, September 2001 36) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder,
37) Sub-investigator, GlaxoSmithKline: Major Depressive Disorder, September 2001 38) Sub-investigator, Pfizer: Major Depressive Disorder with Somatic Symptoms,
39) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity
Laboratories: Adult Attention Deficit Hyperactivity Disorder,
41) Sub-investigator, Novartis: Cerebrovascular Dementia, February 2002 42) Sub-investigator, Eli Lilly: Antipsychotic-induced weight gain, March 2002 43) Sub-investigator, Forest Laboratories: Mild to Moderate Alzheimer's Disease, April
44) Sub-investigator, Pharmacia Upjohn: Generalized Anxiety Disorder, April 2002 45) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, July
Major Depressive Disorder, October 2002
47) Sub-investigator, Eli Lilly: Fibromyalgia with or without depression, November 2002 48) Sub-investigator,
Laboratories: Major Depressive Disorder, November 2002
Sanofi-Synthelabo: Smoking Cessation, November 2002
50) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity
51) Sub-investigator, Johnson & Johnson: Mild Cognitive Impairment, January 2003 52) Sub-investigator,
Sanofi-Synthelabo: Alzheimer's Disease, June 2003
Sanofi-Synthelabo: Major Depressive Disorder, August 2003
55) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, September 2003 56) Sub-investigator,
57) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder,
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
Merck & Co., Inc.: Alzheimer's Disease, November 2003
59) Sub-investigator, Wyeth Research: Alzheimer's Disease, November 2003 60) Principal Investigator, Wyeth Research: Major Depressive Disorder, December 2003 61) Sub-investigator, Cephalon: Pediatric Attention Deficit Hyperactivity Disorder,
62) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder and
63) Principal Investigator, Wyeth Research: Major Depressive Disorder, January 2004 64) Sub-investigator, Sepracor: Insomnia related to Major Depressive Disorder, March
Cephalon: Pediatric Attention Deficit Hyperactivity Disorder, May
66) Sub-investigator, GlaxoSmithKline: Parkinson's Disease, May 2004 67) Sub-investigator,
Sanofi-Synthelabo: Fibromyalgia, June 2004
Laboratories: Adult Attention Deficit Hyperactivity Disorder,
70) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity
71) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity
72) Sub-investigator, Eli Lilly: Major Depressive Disorder, November 2004 73) Sub-investigator, Cephalon: Generalized Anxiety Disorder, November 2004 74) Sub-investigator,
75) Sub-investigator, Cephalon: Generalized Anxiety Disorder, January 2005 76) Sub-investigator, Novartis: Generalized Anxiety Disorder, March 2005 77) Sub-investigator,
Sanofi-Synthelabo: Major Depressive Disorder, March 2005
Laboratories: Adult Attention Deficit Hyperactivity Disorder,
79) Sub-investigator, Cephalon: Narcolepsy in Children and Adolescents, June 2005 80) Sub-investigator, Cephalon: Obstructive Sleep Apnea in Children and Adolescents,
81) Sub-investigator, Eli Lilly: Fibromyalgia, July 2005 82) Sub-investigator,
Cephalon: Excessive Sleepiness in Children and Adolescents, July
83) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity
Laboratories: Adult Attention Deficit Hyperactivity Disorder,
Sanofi-Synthelabo: Generalized Anxiety Disorder, December 2005
86) Sub-investigator, Pfizer/Neurocrine Biosciences: Insomnia and Major Depressive
87) Sub-investigator, Pfizer: Generalized Anxiety Disorder, November 2005 88) Principal Investigator, Wyeth Research: Major Depressive Disorder, February, 2006
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
89) Sub-investigator, Wyeth Research: Fibromyalgia, June 2006 90) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity
91) Sub-investigator, Wyeth Research: Fibromyalgia (Open-label Extension), August 2006 92) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity
93) Sub-investigator, INC Research: Mild Cognitive Impairment following Coronary
94) Sub-investigator, Novartis: Major Depressive Disorder, October 2006 95) Sub-investigator, Eisai: Parkinson's Disease, November 2006 96) Sub-investigator, Wyeth Research: Alzheimer's Disease, November 2006 97) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, December 2006 98) Sub-investigator, Shire Development Inc: Pediatric Attention Deficit Hyperactivity
Disorder with Oppositionality, January 2007
99) Sub-investigator, Eli Lilly: Adult Attention Deficit Hyperactivity Disorder, January
100) Sub-investigator, Shire Pharmaceutical Development Inc: Pediatric Attention Deficit
101) Sub-investigator, Eli Lilly: Chronic Lower Back Pain, January 2007 102) Principal Investigator, Wyeth Research: Major Depressive Disorder, March 2007 103) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity
104) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity
105) Sub-investigator, Eli Lilly: Pediatric Major Depressive Disorder, June 2007 106) Sub-investigator, Wyeth Research: Alzheimer's Disease, June 2007 107) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity
108) Sub-investigator, Abbott Laboratories: Adult Attention Deficit Hyperactivity Disorder,
109) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, August 2007 110) Sub-investigator, Arena Pharmaceuticals, Obesity, January 2008 111) Sub-investigator, Novartis, Major Depressive Disorder, February 2008 112) Sub-investigator, Johnson and Johnson PRD, LLC: Adult Attention Deficit
113) Sub-investigator, Elan: Alzheimer's Disease, April 2008 114) Sub-investigator, Takeda: Major Depressive Disorder, April 2008 115) Sub-investigator, Pfizer Inc: Adults with Nonrestorative Sleep, April 2008 116) Sub-investigator, Sepracor: Pediatric Attention Deficit Hyperactivity Disorder with
117) Sub-investigator, Eli Lilly, Fibromyalgia, June 2008 118) Sub-investigator, Takeda: Generalized Anxiety Disorder, June 2008 119) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, June 2008 120) Sub-investigator, Schering-Plough: Obesity, July 2008
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
121) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity
122) Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, October
123) Sub-investigator, Shire Laboratories, Pediatric Attention Deficit Hyperactivity Disorder
124) Sub-investigator, Pfizer Inc., Generalized Anxiety Disorder (Open-label Extension),
125) Sub-investigator, Pfizer Inc., Alzheimer's Disease, December 2008 126) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, December 2008 127) Sub-investigator, Johnson and Johnson PRD, LLC, Adult Attention Deficit
128) Sub-investigator, Eli Lilly, Osteoarthritis Knee Pain, March 2009 129) Sub-investigator, Neurogen Corporation, Restless Leg Syndrome, April 2009 130) Sub-investigator, Mylan Pharmaceuticals, Inc, Schizophrenia, June 2009 131) Principle Investigator, Wyeth Research, Major Depressive Disorder, June 2009 132) Sub-investigator, Shire Laboratories, Adult Attention Deficit Hyperactivity Disorder,
133) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder, July
134) Principle Investigator, Wyeth Research, Major Depressive Disorder, July 2009 135) Sub-investigator, Pfizer Inc., Sleep Maintenance, July 2009 136) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder (Open-
137) Sub-investigator, Cephalon, Mild to Moderate Closed Traumatic Brain Injury, October
138) Sub-investigator, Eli Lilly, Obesity, October 2009 139) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, October 2009 140) Sub-investigator, Elan, Alzheimer's Disease (Extension), December 2009 141) Sub-investigator, Pfizer, Restless Legs Syndrome, January 2010 142) Sub-investigator, Tibotec Pharmaceuticals, Hepatitis C, January 2010 143) Sub-investigator, Cephalon, Excessive Sleepiness Associated with Shift Work, March
144) Sub-investigator, Forest Laboratories, Major Depressive Disorder, March 2010 145) Sub-investigator, Otsuka, Adult Attention Deficit Hyperactivity Disorder, June 2010 146) Sub-investigator, Novartis, Major Depressive Disorder, July 2010 147) Sub-investigator, Novartis, Migraines, November 2010 148)
Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, December 2010
149) Sub-investigator, Janssen, Alzheimer's Disease, January 2011 150) Sub-investigator, Eli Lilly, Migraines, March 2011 151) Sub-investigator, AstraZeneca, Major Depressive Disorder, May 2011 152) Sub-investigator, Abbott, Major Depressive Disorder, June 2011
CURRICULUM VITAE Rafael A. Rivas-Vazquez, Psy.D.
153) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity
154) Sub-investigator, Shionogi Inc., Pediatric Attention Deficit Hyperactivity Disorder,
155) Sub-investigator, Roche, Multiple Sclerosis, November 2011 156) Sub-investigator, Bristol-Myers Squibb, Migraines, November 2011 157) Sub-investigator, Pfizer, Sensorineural Hearing Loss, December 2011 158) Sub-investigator, Forest Laboratories, Major Depressive Disorder, December 2011
El presente Informe es un documento técnico que refleja la opinión de la JUNTA DE INVESTIGACIONES DE ACCIDENTES DE AVIACIÓN CIVIL con relación a las circunstancias en que se produjo el accidente, objeto de la investi-gación con sus causas y con sus consecue ncias. De conformidad con lo señalado en el Anexo 13 al CONVENIO SOBRE AVIACIÓN CIVIL INTERNACIONAL (Chicago /44) Ratificado por Ley
This article will demonstrate to you why Glutathione is so important to your health and well-being. Glutathione (pronounced 'gloota-thigh-own') is the body's essential health ABC's - Antioxidant, Blood Booster and Cell Detoxifer. It is a tripeptide composed of glutamic, cysteine and glycine. Glutathione is found in all cells in the body, including the bile, the epithelial lining fluid of t